# HMA-Venetoclax Induction in Newly Diagnosed AML

> **NCT07748455** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Pakistan Blood and Marrow Transplant (PBMT) Group** · enrollment: 60 (estimated)

## Conditions studied

- AML
- AML (Acute Myeloid Leukemia)

## Interventions

- **DRUG:** Azacitidine 75 mg/m² SC/IV Days 1-7 + Venetoclax 400 mg orally Days 1-28 (Cycle 1 ramp-up per institutional TLS protocol); 28-day cycles; maximum 2 induction cycles

## Key facts

- **NCT ID:** NCT07748455
- **Lead sponsor:** Pakistan Blood and Marrow Transplant (PBMT) Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07748455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07748455, "HMA-Venetoclax Induction in Newly Diagnosed AML". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07748455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*